Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Best of the Blogs, Biotechnology: Big Pharma Muscles Into Emerging Markets


Plus, private equity labs is Egypt are flourishing.

This column highlights the most interesting and useful business and financial commentary on biotechnology from around the Web.

Wall Street Journal
Link: Big Drug Makers Struggle to Grow in Emerging Markets
"Big drug makers have been reassuring investors: Don't worry about top-selling medicines going off patent. Growth in developing markets, like China and India, will help replace the revenue lost."

"Drug sales in emerging markets will grow by $157 billion over the next five years, reaching at least $345 billion or about a third of the global drug spending, IMS Health predicts. By contrast, the US and European shares of world-wide drug spending are expected to fall as a result of patent expirations, cost cutting and anemic growth."

Link: Private Equity Firms Stimulate Earnings and Deals in Post-Revolution Egypt
"After Abraaj Capital bought a stake in AlBorg Laboratories in May 2008, the Dubai-based private equity firm braced for a rough ride. Over the next four years, AlBorg, an Egyptian medical testing company, weathered the global financial crisis, the economic downturn and the revolutions that swept the Mideast.

"Amid the tumult, private equity companies have had to be opportunistic to drive earnings at their companies. Some have turned to deal-making. AlBorg Laboratories bought a stake in a Sudanese company, Ultralabs, earlier this year, capitalizing on weakness in the region."

Link: Pfizer Settles Impax Patent Suit Over Generic Detrol LA
"The settlement was disclosed in court papers filed in US District Court in Newark, NJ., on Wednesday. Pfizer (PFE) confirmed the accord Thursday, which resolves litigation with Impax but not another company over generic versions of the extended release capsule drug.

"Detrol and Detrol LA had revenues of $400 million in the first half of 2012, Pfizer said in its August 9 quarterly report. Revenues for the drug were down from $455 million during the same period a year earlier."

Link: Bristol-Myers Drops Hepatitis C Drug After Patient Death
"Bristol-Myers Squibb Co. (BMY) has abandoned an experimental hepatitis C pill it bought for $2.5 billion earlier this year after one patient died and others were hospitalized while taking the drug in a study.

"In July, another of the company's experimental prospects, the blood thinner Eliquis being developed with Pfizer Inc., was rejected by US regulators, who asked for more data from existing trials. Approval of the drug may be pushed into next year, according to the company. And the diabetes drug dapagliflozin was rejected in January when the FDA asked for more safety information."

The Economic Times
Link: Private Equity Funds Likely to Fuel Growth in Stem-Cell Banking
"Life Cell with 100 centers across India and over 50,000 clients was the first company in the country to introduce innovations like an insurance policy to help cover stem cell against loss and a monthly installment plan, which makes stem cell banking more affordable to clients."

"Over the last six years, as many as 12 private stem-cell players have entered the industry, pricing their products between Rs 75,000 and Rs 1,50,000."
No positions in stocks mentioned.
Featured Videos